Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer’s Latest Palbociclib Data Could Mean Slimmer Lead Over CDK4/6 Rivals

Executive Summary

Final Phase II data for palbociclib in breast cancer at AACR meeting raise questions about prospects for accelerated approval prior to Phase III results. Meanwhile, Lilly’s bemaciclib emerges as potent monotherapy with seemingly lower risk for neutropenia, but more data are needed to flesh out the drug’s profile.

You may also be interested in...



Keeping Track: Alkermes' Aristada Approval; Bristol's Daklinza Submission; Lilly's Breakthrough

The latest drug development news and highlights from our FDA Performance Tracker.

Combo Trials With Merck, Bristol Highlight Lilly’s Focus On Oncology Going Forward

Combo trials with Opdivo and Keytruda may help Lilly accelerate its move into cancer immunotherapy. Heading out of its patent cliff, the pharma is focused mainly on cancer, diabetes and neurology.

Pfizer Gets Palbociclib To NDA Finish Line On Phase II Data

Pfizer finished a rolling NDA for the high-profile breast cancer drug, the first-in-class CDK-4/6 inhibitor. Whether FDA will agree Phase II data results from the PALOMA-1 trial are sufficient to grant accelerated approval remains to be seen.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS056055

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel